RTP Mobile Logo
Data + Perspectives: Clinical Investigators Explore the Biology Underlying the Role of PARP Inhibition in the Management of Common Cancers (Webinar Video Proceedings)
Released August 2020

Recorded proceedings from a live webinar produced in conjunction with the 2020 AACR Virtual Annual Meeting. Featuring perspectives from Drs Maha Hussain, Ursula Matulonis, Philip A Philip and Hope S Rugo. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists and scientific and research professionals involved in basic, translational and clinical cancer research or treatment.


    • Comprehend how DNA damage repair pathway abnormalities can be targeted via PARP inhibition to elicit benefit in cancer therapy.
    • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among the commercially available and investigational PARP inhibitors to better understand the corresponding activity and toxicities associated with these agents.
    • Appreciate available clinical trial data with FDA-approved PARP inhibitors for patients with ovarian cancer in different disease settings, and safely integrate these agents into routine clinical care.
    • Evaluate the FDA approvals of PARP inhibitors for patients with HER2-negative metastatic breast cancer harboring a germline BRCA mutation, and discern how these agents can be appropriately and safely integrated into routine clinical practice.
    • Appraise available data evaluating olaparib as maintenance therapy for patients with pancreatic cancer with BRCA mutations whose disease has not progressed on first-line platinum-based chemotherapy, and optimally incorporate this FDA-approved treatment strategy into current management algorithms.
    • Review published clinical research findings with PARP inhibitor monotherapy for appropriately selected patients with progressive metastatic castration-resistant prostate cancer, and identify individuals for whom treatment with these agents is appropriate.
    • Understand the biologic rationale for the design of ongoing clinical trials evaluating novel therapeutic approaches with PARP inhibitors for patients with DNA damage repair deficiencies, and as applicable, enroll or refer appropriate individuals for study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Maha Hussain, MD, FACP, FASCO
    Genevieve Teuton Professor of Medicine
    Division of Hematology/Oncology
    Deputy Director
    Robert H Lurie Comprehensive Cancer Center
    Northwestern University Feinberg School of Medicine
    Chicago, Illinois

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Pfizer Inc; CME and Educational Activity: Aptitude Health, Astellas, Sanofi Genzyme.

    Ursula Matulonis, MD
    Chief, Division of Gynecologic Oncology
    Brock-Wilson Family Chair
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Novartis; Consulting Agreement: Merck; Contracted Research: FUJIFILM Pharmaceuticals USA Inc, ImmunoGen Inc, Merck, Mersana Therapeutics, SQZ Biotech; Data and Safety Monitoring Board/Committee: Advaxis Inc; Travel (unpaid advisory board): AstraZeneca Pharmaceuticals LP.

    Philip A Philip, MD, PhD, FRCP
    Kathryn Cramer Endowed Chair in Cancer Research
    Professor of Oncology and Pharmacology
    Leader, GI and Neuroendocrine Oncology
    Karmanos Cancer Institute
    Wayne State University
    Detroit, Michigan

    No financial interests or affiliations to disclose.

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Consulting Agreements: Puma Biotechnology Inc, Samsung Bioepis; Contracted Research: Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seattle Genetics; Paid Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan NV, Novartis, Pfizer Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.

    Release date: August 2020
    Expiration date: August 2021

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):